



## Clinical trial results:

### A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed

#### Summary

EudraCT number	2015-004025-14
Trial protocol	GB BE DE ES
Global end of trial date	23 October 2019

#### Results information

Result version number	v1 (current)
This version publication date	07 November 2020
First version publication date	07 November 2020

#### Trial information

##### Trial identification

Sponsor protocol code	GS-US-380-1844
-----------------------	----------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02603120
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
Scientific contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 October 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 May 2017
Global end of trial reached?	Yes
Global end of trial date	23 October 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus-1 (HIV-1) infected adults.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements. This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 November 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 62
Country: Number of subjects enrolled	United Kingdom: 8
Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	France: 12
Country: Number of subjects enrolled	Germany: 28
Country: Number of subjects enrolled	Australia: 15
Country: Number of subjects enrolled	Canada: 35
Country: Number of subjects enrolled	Italy: 2
Country: Number of subjects enrolled	United States: 403
Worldwide total number of subjects	567
EEA total number of subjects	114

Notes:

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	543
From 65 to 84 years	24
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled at study sites in North America, Europe, and Australia. The first participant was screened on 11 November 2015. The last study visit occurred on 23 October 2019.

### Pre-assignment

Screening details:

646 participants were screened.

### Period 1

Period 1 title	Double-Blind Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	B/F/TAF

Arm description:

B/F/TAF 50/200/25 mg FDC tablet + ABC/DTG/3TC placebo orally once daily for at least 48 weeks, without regard to food.

Arm type	Experimental
Investigational medicinal product name	B/F/TAF
Investigational medicinal product code	
Other name	Biktarvy® (BVY)
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

B/F/TAF 50/200/25 mg FDC tablet administered orally once daily.

Investigational medicinal product name	ABC/DTG/3TC placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

ABC/DTG/3TC placebo tablet administered orally once daily .

<b>Arm title</b>	ABC/DTG/3TC
------------------	-------------

Arm description:

ABC/DTG/3TC (600/50/300 mg) FDC tablet + B/F/TAF placebo orally once daily for at least 48 weeks, without regard to food.

Arm type	Experimental
Investigational medicinal product name	ABC/DTG/3TC
Investigational medicinal product code	
Other name	Triumeq®
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

ABC/DTG/3TC (600/50/300 mg) FDC tablet administered orally once daily.

Investigational medicinal product name	B/F/TAF placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

B/F/TAF placebo tablet administered orally once daily .

<b>Number of subjects in period 1<sup>[1]</sup></b>	B/F/TAF	ABC/DTG/3TC
Started	282	281
Completed	265	267
Not completed	17	14
Adverse event, non-fatal	3	3
Death	2	-
Pregnancy	1	1
Non-compliance with study drug	1	-
Withdrew consent	4	8
Lost to follow-up	4	2
Investigator's discretion	2	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 567 participants were randomized but 4 participants did not received study drug.

## Period 2

Period 2 title	Open-Label Phase
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	B/F/TAF from B/F/TAF

Arm description:

Participants who received B/F/TAF in double-blind phase and from country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.

Arm type	Experimental
Investigational medicinal product name	B/F/TAF
Investigational medicinal product code	
Other name	Biktarvy® (BVY)
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

B/F/TAF (50/200/25 mg) FDC tablet administered orally once daily.

<b>Arm title</b>	B/F/TAF from ABC/DTG/3TC
Arm description:	
Participants who received ABC/DTG/3TC in double-blind phase and from country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.	
Arm type	Experimental
Investigational medicinal product name	B/F/TAF
Investigational medicinal product code	
Other name	Biktarvy® (BVY)
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

B/F/TAF (50/200/25 mg) FDC tablet administered orally once daily.

<b>Number of subjects in period 2<sup>[2]</sup></b>	B/F/TAF from B/F/TAF	B/F/TAF from ABC/DTG/3TC
Started	259	265
Completed	254	254
Not completed	5	11
Adverse event, non-fatal	-	1
Death	-	1
Lost to follow-up	3	4
Investigator's discretion	1	2
Withdrew consent	1	2
Lack of efficacy	-	1

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: 532 participants completed the Double-Blind Phase, but 8 participants did not enter in the Open-Label Phase.

## Baseline characteristics

### Reporting groups

Reporting group title	B/F/TAF
-----------------------	---------

Reporting group description:

B/F/TAF 50/200/25 mg FDC tablet + ABC/DTG/3TC placebo orally once daily for at least 48 weeks, without regard to food.

Reporting group title	ABC/DTG/3TC
-----------------------	-------------

Reporting group description:

ABC/DTG/3TC (600/50/300 mg) FDC tablet + B/F/TAF placebo orally once daily for at least 48 weeks, without regard to food.

Reporting group values	B/F/TAF	ABC/DTG/3TC	Total
Number of subjects	282	281	563
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	46	45	
standard deviation	± 11.1	± 11.5	-

Gender categorical			
Units: Subjects			
Female	35	29	64
Male	247	252	499

Race			
------	--	--	--

Not Permitted = local regulators did not allow collection of race or ethnicity information.

Units: Subjects			
American Indian or Alaska Native	2	2	4
Asian	9	9	18
Black	59	62	121
Native Hawaiian or Pacific Islander	3	0	3
White	206	202	408
Other	3	3	6
Not Permitted	0	3	3

Ethnicity			
-----------	--	--	--

Not Permitted = local regulators did not allow collection of race or ethnicity information.

Units: Subjects			
Hispanic or Latino	46	52	98
Not Hispanic or Latino	236	227	463
Not Permitted	0	2	2

Region of Enrollment			
Units: Subjects			

Canada	13	22	35
Belgium	1	1	2
United States	203	198	401
Italy	1	1	2
United Kingdom	3	3	6

France	4	8	12
Germany	17	11	28
Spain	31	31	62
Australia	9	6	15
HIV-1 RNA Categories			
Units: Subjects			
< 50 copies/mL	278	272	550
≥ 50 copies/mL	4	9	13
CD4 Cell Count Category			
Units: Subjects			
≥ 50 to < 200 cells/μL	6	4	10
≥ 200 to < 350 cells/μL	16	30	46
≥ 350 to < 500 cells/μL	33	42	75
≥ 500 cells/μL	227	205	432
CD4 Cell Count			
Units: cell/μL			
arithmetic mean	752	694	
standard deviation	± 302.2	± 291.6	-



## End points

### End points reporting groups

Reporting group title	B/F/TAF
Reporting group description: B/F/TAF 50/200/25 mg FDC tablet + ABC/DTG/3TC placebo orally once daily for at least 48 weeks, without regard to food.	
Reporting group title	ABC/DTG/3TC
Reporting group description: ABC/DTG/3TC (600/50/300 mg) FDC tablet + B/F/TAF placebo orally once daily for at least 48 weeks, without regard to food.	
Reporting group title	B/F/TAF from B/F/TAF
Reporting group description: Participants who received B/F/TAF in double-blind phase and from country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.	
Reporting group title	B/F/TAF from ABC/DTG/3TC
Reporting group description: Participants who received ABC/DTG/3TC in double-blind phase and from country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.	

### Primary: Percentage of Participants With Virologic Failure (HIV-1 RNA $\geq$ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm

End point title	Percentage of Participants With Virologic Failure (HIV-1 RNA $\geq$ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm
End point description: The percentage of participants achieving HIV-1 RNA $\geq$ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The Full Analysis Set included participants who were randomized into the study and received at least 1 dose of study drug.	
End point type	Primary
End point timeframe: Week 48	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	282	281		
Units: percentage of participants				
number (not applicable)	1.1	0.4		

### Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis- B/F/TAF vs ABC/DTG/3TC
Statistical analysis description:	
The differences in percentages of participants between treatment groups and their 95.002% CIs were calculated based on an unconditional exact method using 2 inverted 1-sided tests.	
Comparison groups	ABC/DTG/3TC v B/F/TAF
Number of subjects included in analysis	563
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[1]</sup>
Parameter estimate	Difference in Percentages
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	2.8

Notes:

[1] - A sample size of 260 participants per treatment group would provide at least 90% power to detect a noninferiority margin of 4% in difference in percentage of participants with HIV-1 RNA  $\geq$  50 copies/mL at Wk 48, between B/F/TAF group and ABC/DTG/3TC group. Sample size was based on assumptions that both treatment groups have 2% of participants with HIV-1 RNA  $\geq$  50 copies/mL at Wk 48 and that the non-inferiority margin is 4%, and that the significance level of the test is at a one-sided 0.025 level.

<b>Statistical analysis title</b>	Statistical analysis- B/F/TAF vs ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	563
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.62
Method	Fisher exact

### **Secondary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm**

End point title	Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm
-----------------	--

End point description:

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis were analysed.

End point type	Secondary
End point timeframe:	
Week 48	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	282	281		
Units: percentage of participants				
number (not applicable)	93.6	95.0		

## Statistical analyses

Statistical analysis title	Statistical analysis- B/F/TAF vs ABC/DTG/3TC
Statistical analysis description:	
The differences in percentages of participants between treatment groups and their 95.002% CIs were calculated based on an unconditional exact method using 2 inverted 1-sided tests.	
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	563
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[2]</sup>
Parameter estimate	Difference in Percentages
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.5
upper limit	2.6

Notes:

[2] - It would be concluded that B/F/TAF is noninferior to ABC/DTG/3TC if the lower bound of the 2-sided 95.002% CI of the difference between treatment groups (B/F/TAF group -ABC/DTG/3TC group) in the percentage of participants with HIV-1 RNA < 50 copies/mL is greater than -10%.

Statistical analysis title	Statistical analysis- B/F/TAF vs ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	563
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.59
Method	Fisher exact

## Secondary: Change From Baseline in CD4+ Cell Count at Week 48

End point title	Change From Baseline in CD4+ Cell Count at Week 48
End point description:	
Participants in the Full Analysis Set with available data were analyzed.	
End point type	Secondary
End point timeframe:	
Baseline; Week 48	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	265	267		
Units: cells/ $\mu$ L				
arithmetic mean (standard deviation)	-31 ( $\pm$ 181.3)	4 ( $\pm$ 191.0)		

## Statistical analyses

Statistical analysis title	Statistical analysis- B/F/TAF vs ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.031
Method	ANOVA
Parameter estimate	Difference in least squares means
Point estimate	-35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-67
upper limit	-3

## Secondary: Spine Bone Mineral Density (BMD) at Baseline

End point title	Spine Bone Mineral Density (BMD) at Baseline
End point description:	The Spine dual X-ray absorptiometry (DXA) Analysis Set included participants who were randomized into the study, received at least 1 dose of study drug, and had nonmissing baseline spine BMD values.
End point type	Secondary
End point timeframe:	
Baseline	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	256	262		
Units: g/cm <sup>2</sup>				
arithmetic mean (standard deviation)	1.124 ( $\pm$ 0.1833)	1.103 ( $\pm$ 0.1548)		

## Statistical analyses

**Secondary: Percentage Change From Baseline in Spine BMD at Week 48**

End point title	Percentage Change From Baseline in Spine BMD at Week 48
End point description: Participants in the Spine DXA Analysis Set with available data were analyzed.	
End point type	Secondary
End point timeframe: Baseline; Week 48	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	233	244		
Units: percentage change				
arithmetic mean (standard deviation)	0.692 ( $\pm$ 3.1296)	0.416 ( $\pm$ 2.9973)		

**Statistical analyses**

<b>Statistical analysis title</b>	Statistical analysis- B/F/TAF vs ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	477
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.33
Method	ANOVA
Parameter estimate	Difference in least squares means
Point estimate	0.276
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.275
upper limit	0.827

**Secondary: Hip Bone Mineral Density at Baseline**

End point title	Hip Bone Mineral Density at Baseline
End point description: The Hip DXA Analysis Set included participants who were randomized into the study, received at least 1 dose of study drug, and had nonmissing baseline hip BMD values.	
End point type	Secondary
End point timeframe: Baseline	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	256	265		
Units: g/cm <sup>2</sup>				
arithmetic mean (standard deviation)	1.006 (± 0.1471)	0.996 (± 0.1363)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage Change From Baseline in Hip BMD at Week 48

End point title	Percentage Change From Baseline in Hip BMD at Week 48
End point description:	Participants in the Hip DXA Analysis Set with available data were analyzed.
End point type	Secondary
End point timeframe:	Baseline; Week 48

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	229	242		
Units: percentage change				
arithmetic mean (standard deviation)	0.156 (± 2.2138)	0.299 (± 2.1077)		

## Statistical analyses

Statistical analysis title	Statistical analysis- B/F/TAF vs ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	471
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.47
Method	ANOVA
Parameter estimate	Difference in least squares means
Point estimate	-0.143

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.534
upper limit	0.248

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

First dose date up to Week 169 plus 30 days

Adverse event reporting additional description:

The Safety Analysis Set included participants who were randomized into the study and received at least 1 dose of study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

### Reporting groups

Reporting group title	Double-Blind: B/F/TAF
-----------------------	-----------------------

Reporting group description:

B/F/TAF 50/200/25 mg FDC tablet + ABC/DTG/3TC placebo orally once daily for at least 48 weeks, without regard to food.

Reporting group title	Double-Blind: ABC/DTG/3TC
-----------------------	---------------------------

Reporting group description:

ABC/DTG/3TC (600/50/300 mg) FDC tablet + B/F/TAF placebo orally once daily for at least 48 weeks, without regard to food.

Reporting group title	Open-label Extension: B/F/TAF from B/F/TAF
-----------------------	--

Reporting group description:

Participants who received B/F/TAF in double-blind phase and from country where B/F/TAF was not available was given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.

Reporting group title	Open-label Extension: B/F/TAF from ABC/DTG/3TC
-----------------------	--

Reporting group description:

Participants who received ABC/DTG/3TC in double-blind phase and from country where B/F/TAF was not available was given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.

Serious adverse events	Double-Blind: B/F/TAF	Double-Blind: ABC/DTG/3TC	Open-label Extension: B/F/TAF from B/F/TAF
Total subjects affected by serious adverse events			
subjects affected / exposed	17 / 282 (6.03%)	26 / 281 (9.25%)	24 / 259 (9.27%)
number of deaths (all causes)	2	0	1
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Brain cancer metastatic			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Lung adenocarcinoma			



subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Malignant neoplasm of thymus			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningioma			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular seminoma (pure) stage I			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Drug withdrawal syndrome			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden cardiac death			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			

subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	2 / 282 (0.71%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	2 / 282 (0.71%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abnormal behaviour			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol abuse			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			

subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression suicidal			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranoia			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Schizophrenia			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Self-injurious ideation			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance abuse			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar disorder			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional overdose			

subjects affected / exposed	2 / 282 (0.71%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	2 / 282 (0.71%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol poisoning			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin laceration			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			

subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Myocardial bridging			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 282 (0.35%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 282 (0.00%)	2 / 281 (0.71%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive heart disease			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hemiplegic migraine			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebrobasilar insufficiency			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Macular detachment			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitreous haemorrhage			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Duodenal ulcer			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			

subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal stenosis			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Infections and infestations Abscess limb subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	  0 / 282 (0.00%) 0 / 0 0 / 0	  2 / 281 (0.71%) 0 / 2 0 / 0	  0 / 259 (0.00%) 0 / 0 0 / 0
Appendicitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 282 (0.00%) 0 / 0 0 / 0	 1 / 281 (0.36%) 0 / 1 0 / 0	 1 / 259 (0.39%) 0 / 1 0 / 0
Large intestine infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 282 (0.35%) 0 / 1 0 / 0	 1 / 281 (0.36%) 0 / 1 0 / 0	 0 / 259 (0.00%) 0 / 0 0 / 0
Shigella infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 282 (0.00%) 0 / 0 0 / 0	 1 / 281 (0.36%) 0 / 1 0 / 0	 1 / 259 (0.39%) 0 / 1 0 / 0
Acute hepatitis C subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 282 (0.00%) 0 / 0 0 / 0	 0 / 281 (0.00%) 0 / 0 0 / 0	 1 / 259 (0.39%) 0 / 1 0 / 0
Anal abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 282 (0.00%) 0 / 0 0 / 0	 1 / 281 (0.36%) 0 / 1 0 / 0	 0 / 259 (0.00%) 0 / 0 0 / 0
Cellulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 282 (0.00%) 0 / 0 0 / 0	 1 / 281 (0.36%) 0 / 1 0 / 0	 0 / 259 (0.00%) 0 / 0 0 / 0
Cellulitis of male external genital organ subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 282 (0.00%) 0 / 0 0 / 0	 1 / 281 (0.36%) 0 / 1 0 / 0	 0 / 259 (0.00%) 0 / 0 0 / 0

Endocarditis			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye infection syphilitic			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis bacterial			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural sepsis			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
subjects affected / exposed	0 / 282 (0.00%)	1 / 281 (0.36%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 282 (0.00%)	0 / 281 (0.00%)	1 / 259 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	1 / 282 (0.35%)	0 / 281 (0.00%)	0 / 259 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Open-label Extension: B/F/TAF from ABC/DTG/3TC		
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 265 (4.15%)		
number of deaths (all causes)	1		
number of deaths resulting from			

adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Brain cancer metastatic			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant neoplasm of thymus			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningioma			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Testicular seminoma (pure) stage I			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Drug withdrawal syndrome			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sudden cardiac death			

subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Asthma			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumothorax			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abnormal behaviour			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Alcohol abuse				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anxiety				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Depression suicidal				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Paranoia				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Schizophrenia				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Self-injurious ideation				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Substance abuse				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bipolar disorder				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Injury, poisoning and procedural complications				

Ankle fracture				
subjects affected / exposed	1 / 265 (0.38%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Intentional overdose				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Overdose				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Toxicity to various agents				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Alcohol poisoning				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Femur fracture				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Head injury				
subjects affected / exposed	1 / 265 (0.38%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Skin laceration				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper limb fracture				

subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wrist fracture			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Myocardial bridging			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertensive heart disease			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		



Epilepsy			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hemiplegic migraine			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Macular detachment			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal detachment			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vitreous haemorrhage			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis ulcerative			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Diarrhoea				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Duodenal ulcer				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastric ulcer				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemorrhoidal haemorrhage				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hiatus hernia				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Inguinal hernia				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal obstruction				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Umbilical hernia				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary disorders				

Bile duct stone			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Spinal stenosis			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abscess limb			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestine infection			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Shigella infection			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute hepatitis C			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal abscess			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis of male external genital			

organ				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endocarditis				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia infection				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Eye infection syphilitic				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis viral				
subjects affected / exposed	1 / 265 (0.38%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Herpes zoster				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lymphadenitis bacterial				
subjects affected / exposed	0 / 265 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteomyelitis				

subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post procedural sepsis			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tooth abscess			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound infection			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypovolaemia			
subjects affected / exposed	0 / 265 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Double-Blind: B/F/TAF	Double-Blind: ABC/DTG/3TC	Open-label Extension: B/F/TAF from B/F/TAF
Total subjects affected by non-serious adverse events			
subjects affected / exposed	122 / 282 (43.26%)	132 / 281 (46.98%)	84 / 259 (32.43%)
Nervous system disorders			
Headache			
subjects affected / exposed	19 / 282 (6.74%)	23 / 281 (8.19%)	5 / 259 (1.93%)
occurrences (all)	21	25	5
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	26 / 282 (9.22%)	18 / 281 (6.41%)	20 / 259 (7.72%)
occurrences (all)	27	22	27
Nausea			
subjects affected / exposed	6 / 282 (2.13%)	16 / 281 (5.69%)	3 / 259 (1.16%)
occurrences (all)	6	16	3
Psychiatric disorders			
Insomnia			
subjects affected / exposed	9 / 282 (3.19%)	22 / 281 (7.83%)	1 / 259 (0.39%)
occurrences (all)	9	22	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	21 / 282 (7.45%)	18 / 281 (6.41%)	8 / 259 (3.09%)
occurrences (all)	22	18	8
Back pain			
subjects affected / exposed	13 / 282 (4.61%)	13 / 281 (4.63%)	13 / 259 (5.02%)
occurrences (all)	15	14	13
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	34 / 282 (12.06%)	32 / 281 (11.39%)	22 / 259 (8.49%)
occurrences (all)	37	42	27
Nasopharyngitis			
subjects affected / exposed	21 / 282 (7.45%)	22 / 281 (7.83%)	20 / 259 (7.72%)
occurrences (all)	26	30	30
Sinusitis			

subjects affected / exposed	11 / 282 (3.90%)	15 / 281 (5.34%)	9 / 259 (3.47%)
occurrences (all)	11	15	11
Bronchitis			
subjects affected / exposed	11 / 282 (3.90%)	15 / 281 (5.34%)	11 / 259 (4.25%)
occurrences (all)	12	16	13

<b>Non-serious adverse events</b>	Open-label Extension: B/F/TAF from ABC/DTG/3TC		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	82 / 265 (30.94%)		
Nervous system disorders			
Headache			
subjects affected / exposed	9 / 265 (3.40%)		
occurrences (all)	9		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	11 / 265 (4.15%)		
occurrences (all)	12		
Nausea			
subjects affected / exposed	1 / 265 (0.38%)		
occurrences (all)	1		
Psychiatric disorders			
Insomnia			
subjects affected / exposed	7 / 265 (2.64%)		
occurrences (all)	7		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	6 / 265 (2.26%)		
occurrences (all)	6		
Back pain			
subjects affected / exposed	6 / 265 (2.26%)		
occurrences (all)	6		
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	26 / 265 (9.81%)		
occurrences (all)	34		
Nasopharyngitis			



subjects affected / exposed	22 / 265 (8.30%)		
occurrences (all)	27		
Sinusitis			
subjects affected / exposed	13 / 265 (4.91%)		
occurrences (all)	16		
Bronchitis			
subjects affected / exposed	8 / 265 (3.02%)		
occurrences (all)	11		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 February 2016	The following changes were made: 1. Additional investigational centers were included to expand the number of sites participating. 2. Updated inclusion criterion to remove the limit of number of prior regimens at screening. 3. Clarified criteria for discontinuation of study treatment and for management of laboratory toxicity. 4. Included guidance for management of potential hepatobiliary toxicity.
19 October 2016	The following changes were made: 1. Revised the number of centers participating in the study. 2. Revised prior and concomitant medications. 3. Added OL rollover extension and treatment assessments for participants who receive OL B/F/TAF for up to 96 weeks. 4. Clarified that participants were only receive OL B/F/TAF if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data. 5. Updated the Early Study Drugs Discontinuation (ESDD) assessments for participants who discontinue during the OL rollover extension. 6. Added hepatitis B virus (HBV) and hepatitis C virus (HCV) serology testing at Week 48 and every 48 weeks in the OL extension (Weeks 48 and 96 OL). 7. Revised Gilead reporting requirements to clarify that, in addition to using the reference safety information in the investigator's brochure and relevant local label as applicable, Gilead may also use the European Union (EU) summary of product characteristics (SmPC) for assessment of expectedness of serious adverse events (SAEs) for ABC/DTG/3TC. 8. Revised the definition of special situations.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/31430369>

<http://www.ncbi.nlm.nih.gov/pubmed/29925489>